Inconsistent with data from CML cell lines, no substantial differences in the ABCG2+ phenotype and ABCG2 mRNA levels were detected among different stages of CML blasts and normal cells. This evidence concerns the gene ABCG2 and chronic myelogenous leukemia, BCR-ABL1 positive.